Trial Profile
A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.